How to Prescribe Journavx (Suzetrigine)
Journavx is indicated for moderate to severe acute pain in adults, with a standard dosing regimen of 100 mg loading dose on an empty stomach, followed by 50 mg every 12 hours starting 12 hours later, taken with or without food. 1
Standard Dosing Protocol
Initial Dose (Dose 1)
- 100 mg orally as a loading dose
- Must be taken on an empty stomach (at least 1 hour before or 2 hours after food) to avoid delayed onset of action
- Clear liquids are permitted (water, apple juice, vegetable broth, tea, black coffee)
- Swallow tablets whole—do not chew or crush 1
Maintenance Doses (Starting 12 hours after initial dose)
- 50 mg orally every 12 hours
- Can be taken with or without food
- Continue for shortest duration needed (not studied beyond 14 days) 1
Key Dietary Restriction
- Avoid grapefruit in any form (food or drink) during treatment 1
Dose Adjustments for Hepatic Impairment
Severe Hepatic Impairment (Child-Pugh Class C)
- Avoid use entirely 1
Moderate Hepatic Impairment (Child-Pugh Class B)
- Doses 1-4: Same as standard (100 mg loading, then 50 mg every 12 hours for 3 doses)
- Dose 5 and beyond: Reduce to 50 mg every 24 hours (not every 12 hours) 1
Mild Hepatic Impairment (Child-Pugh Class A)
- No adjustment needed—use standard dosing 1
Dose Adjustments for Drug Interactions
Strong CYP3A Inhibitors
- Contraindicated—do not prescribe Journavx 1
Moderate CYP3A Inhibitors
- Doses 1-4: Same as standard (100 mg loading, then 50 mg every 12 hours for 3 doses)
- Dose 5 and beyond: Reduce to 50 mg every 24 hours 1
Common moderate CYP3A inhibitors include diltiazem, verapamil, fluconazole, and erythromycin. This dosing adjustment mirrors the hepatic impairment protocol because both conditions increase suzetrigine exposure 1, 2.
Missed Dose Management
For Patients WITHOUT Hepatic Impairment or CYP3A Inhibitors
- 1 missed dose: Take as soon as possible, then resume regular schedule
- 2+ missed doses: Take 2 tablets (100 mg), then resume regular schedule 1
For Patients WITH Hepatic Impairment or Taking Moderate CYP3A Inhibitors
- Take missed dose as soon as possible
- If next scheduled dose is within 6 hours, skip that dose and resume regular schedule 1
Clinical Considerations
Efficacy Timeline
- Pain relief typically occurs within 2-4 hours of the loading dose 2, 3
- In clinical trials, 83-91% of patients rated analgesia as good to excellent 2
- Demonstrated non-inferiority to hydrocodone/acetaminophen 5/325 mg in post-surgical pain 2, 4
Multimodal Approach
Journavx works best as part of multimodal analgesia. In a phase 4 study, 90.9% of patients rated pain control as good/very good/excellent when suzetrigine was combined with acetaminophen and ibuprofen, and 76.1% required no opioid rescue 5. If pain remains inadequate after 2-4 hours, supplement with other non-opioid analgesics or opioids as needed 2.
Special Populations
- Renal impairment: Dosage adjustment required but specific recommendations not detailed in available labeling 4
- Pregnancy/lactation: Safety not established
- Pediatrics: Not approved for use in children 1
Common Adverse Effects
- Itching
- Muscle spasms
- Elevated creatine phosphokinase
- Rash
- Generally well-tolerated with fewer side effects than opioids 1, 2
Practical Prescribing Pitfalls
- Prior authorization: May be required by insurance—verify before discharge 2
- Empty stomach requirement: Only applies to the loading dose; patients often miss this instruction 1
- CYP3A interactions: Screen for strong inhibitors (ketoconazole, clarithromycin, ritonavir) which contraindicate use, and moderate inhibitors which require dose reduction 1, 2
- Duration limit: Not studied beyond 14 days—this is for acute pain only 1
- Grapefruit: Patients must avoid throughout treatment as it acts as a CYP3A inhibitor 1